L3VLUP
ProSign in

MDT · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

MDTJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • MDT
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterMDTJNJ
Q3 202032 holders, $18.3bn30 holders, $26.2bn
Q4 202033 holders, $20.0bn32 holders, $26.6bn
Q1 202137 holders, $20.8bn31 holders, $25.3bn
Q2 202134 holders, $22.1bn37 holders, $25.6bn
Q3 202132 holders, $21.6bn40 holders, $24.1bn
Q4 202131 holders, $18.5bn33 holders, $25.2bn
Q1 202228 holders, $18.0bn35 holders, $28.2bn
Q2 202235 holders, $15.2bn33 holders, $26.9bn
Q3 202233 holders, $13.7bn36 holders, $25.4bn
Q4 202232 holders, $13.4bn35 holders, $27.6bn
Q1 202325 holders, $13.6bn42 holders, $24.5bn
Q2 202330 holders, $15.2bn38 holders, $25.0bn
Q3 202328 holders, $13.1bn37 holders, $18.9bn
Q4 202324 holders, $12.7bn31 holders, $19.0bn
Q1 202419 holders, $12.8bn32 holders, $19.7bn
Q2 202426 holders, $11.2bn35 holders, $20.4bn
Q3 202430 holders, $13.9bn28 holders, $22.3bn
Q4 202433 holders, $11.5bn37 holders, $20.4bn
Q1 202527 holders, $13.8bn32 holders, $20.5bn
Q2 202530 holders, $13.3bn31 holders, $18.4bn
Q3 202525 holders, $13.6bn32 holders, $23.7bn
Q4 202527 holders, $14.9bn29 holders, $27.8bn
Q1 202624 holders, $14.3bn34 holders, $35.6bn
Q2 202629 holders, $12.8bn33 holders, $39.1bn
MDT

Medtronic PLC

Holders
24
Reported value
$12.7bn
Buyers
9
Sellers
17

Breadth -8 among 93 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
JNJ

Johnson & Johnson

Holders
31
Reported value
$19.0bn
Buyers
16
Sellers
16

Breadth 0 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2023

Among the 40 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only MDT (9)

Arrowstreet Capital LP, Artisan Partners LP, Baillie Gifford & Co, Brevan Howard Capital Management LP, First Eagle Investment Management LLC, Holocene Advisors LP, Millennium Management LLC, Point72 Asset Management LP, Polen Capital Management LLC

Only JNJ (16)

Acadian Asset Management LLC, Bridgewater Associates LP, Caxton Associates LLP, D. E. Shaw & Co., Fidelity (FMR LLC), GAMCO Investors Inc, Hudson Bay Capital Management LP, Jane Street Group LLC, Markel Group Inc, Neuberger Berman Group LLC, Quantbot Technologies LP, Susquehanna International Group LLP, Tudor Investment Corp, Two Sigma Investments LP, Verition Fund Management LLC, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →